Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 5191SC

5191SC 10 µg (With Carrier)
5191SF 10 µg (Carrier Free)
5191LC 50 µg (With Carrier)
5191LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant mouse GM-CSF (mGM-CSF) Ala18-Lys141 (Accession #NP_034099) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mGM-CSF. All lots are greater than 98% pure.


Molecular Formula:

Recombinant mGM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 14,112.1. DTT-reduced protein migrates as a 22 kDa polypeptide and non-reduced protein migrates as a 19 kDa polypeptide due to intramolecular cystines. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal APTRS of recombinant mGM-CSF was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant mGM-CSF was determined in a MC/9 cell proliferation assay. The ED50 of each lot is between 6-25 pg/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg mGM-CSF.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mGM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

GM-CSF is produced by activated T cells, NK cells and macrophages (1,2). Target cells include granulocytes, monocyte precursors and subsets of differentiated myeloid cells (1,3,4). Many target cells require GM-CSF for survival. GM-CSF induces proliferation, is involved in the hematopoietic differentiation of dendritic cells and is a key factor in differentiation pathways leading from stem cells. GM-CSF activates effector functions of myeloid cells, thereby linking adaptive and innate immunity and in turn may boost anti-tumor immunity (5). GM-CSF receptor is composed of GM-CSFRα and the common β chain, βC, which is also utilized by IL-3 and IL-5 (1). Binding of GM-CSF initiates the Jak2, Stat5 and PI3K/Akt pathways (1).


1.  Guthridge, M.A. et al. (1998) Stem Cells 16, 301-13.

2.  Sonoda, Y. et al. (1988) Proc Natl Acad Sci USA 85, 4360-4.

3.  Sonoda, Y. et al. (1988) Blood 72, 1381-6.

4.  de la Cruz-Merino, L. et al. (2008) Oncologist 13, 1246-54.

5.  Zhang, A.L. et al. (2007) Blood 110, 2484-93.


Entrez-Gene Id 12981
Swiss-Prot Acc. P01587


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.